Algae are a rich source of bioactive compounds that have a wide range of beneficial effects on human health and can show significant potential in the treatment of hematological malignancies such as leukemia, lymphoma, and multiple myeloma. These diseases often pose a therapeutic challenge despite recent advances in treatment (e.g., the use of immunomodulatory drugs, proteasome inhibitors, CD38 monoclonal antibodies, stem cell transplant, and targeted therapy). A considerable number of patients experience relapses or resistance to the applied therapies. Algal compounds, alone or in combination with chemotherapy or other more advanced therapies, have exhibited antitumor and immunomodulatory effects in preclinical studies that may improve disease outcomes. These include the ability to induce apoptosis, inhibit tumor growth, and improve immune responses. However, most of these studies are conducted in vitro, often without in vivo validation or clinical trials. This paper summarizes the current evidence on the in vitro effects of algae extracts and isolated compounds on leukemia, lymphoma, and myeloma cell lines. In addition, we address the current advances in the application of algae-derived compounds as targeted drug carriers and their synergistic potential against hematologic malignancies.
藻类是生物活性化合物的丰富来源，这些化合物对人类健康具有广泛的有益作用，并在治疗白血病、淋巴瘤和多发性骨髓瘤等血液系统恶性肿瘤方面展现出显著潜力。尽管近年来治疗手段有所进展（例如使用免疫调节药物、蛋白酶体抑制剂、CD38单克隆抗体、干细胞移植及靶向治疗），这些疾病仍常构成治疗挑战。相当数量的患者会出现复发或对现有疗法产生耐药性。临床前研究表明，藻类提取物单独使用或与化疗及其他先进疗法联用，均显示出可能改善疾病预后的抗肿瘤和免疫调节作用，包括诱导细胞凋亡、抑制肿瘤生长及增强免疫应答的能力。然而，目前大多数研究仍停留在体外实验阶段，往往缺乏体内验证或临床试验支持。本文综述了当前关于藻类提取物及其分离化合物对白血病、淋巴瘤和骨髓瘤细胞系体外作用的研究证据，并探讨了藻源化合物作为靶向药物载体的应用进展及其对抗血液恶性肿瘤的协同潜力。
Unlocking the Therapeutic Potential of Algae-Derived Compounds in Hematological Malignancies
肿瘤(癌症)患者之家